NASDAQ NMS - GLOBAL MARKET · AUPH
+1.47% · +$0.2200 · Vol 1.0M
After hours · updated 16:29:00 ET
Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Biotechnology
$15.15
Card
Relationship Map

Veridion Score

BETAMEDIUM CONF · 5/6 factorsMethodology
AUPH
Aurinia Pharmaceuticals Inc
Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

67/ 100
Veridion Score
BUY BIAS · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Stale score · Tue Aug 4 · completed session · 22h old · Scheduled each trading day · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is AUPH moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading AUPH catalysts
About Aurinia Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2009
Employees
128
Country
CA

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$15.05
Day high
$15.24
Day low
$14.89
Previous close
$14.93
52W high
$18.62
-18.64% from high
52W low
$11.05
54% of range
Market cap
$1.9B
P/E
6.53×
EPS
$0.8000
Beta
0.64
Shares out
128.6M
Volume
1M
0.63× rel vol
Avg volume
1.6M
VWAP
$15.16
Price history computed in-house
1W
-0.20%
1M
-2.19%
3M
+0.07%
1Y
+29.49%
YTD
-5.02%
SMA 50 $15.89 · below
SMA 200 $15.20 · below
52W position 54%

AUPH overview

Veridion Score
67
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around AUPH.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading AUPH Form 4 filings
Public disclosures

Congress activity in AUPH

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for AUPH in the cached public ledger.

Federal contracts

AUPH contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AUPH in this window.
Lobbying spend

AUPH lobbying filings, year to date.

Registered lobbying filings matched to Aurinia Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for AUPH in this window.
Loading news for AUPH
Analyst ratings
Sovereign unlock shows live analyst consensus for AUPH.
Options
Sovereign unlock shows live options positioning for AUPH.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.